Long-Term Visceral Hypersensitivity Following Induction of Chemical
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity. -
Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and O
pharmaceutics Article Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and O-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling Hyeon-Cheol Jeong 1, Soo Hyeon Bae 2 , Jung-Woo Bae 3, Sooyeun Lee 3, Anhye Kim 4 , Yoojeong Jang 1 and Kwang-Hee Shin 1,* 1 College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea; [email protected] (H.-C.J.); [email protected] (Y.J.) 2 Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea; [email protected] 3 College of Pharmacy, Keimyung University, Daegu 42601, Korea; [email protected] (J.-W.B.); [email protected] (S.L.) 4 Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-53-950-8582 Received: 6 October 2019; Accepted: 15 November 2019; Published: 17 November 2019 Abstract: Tramadol is a µ-opioid receptor agonist and a monoamine reuptake inhibitor. O-desmethyltramadol (M1), the major active metabolite of tramadol, is produced by CYP2D6. A physiologically-based pharmacokinetic model was developed to predict changes in time-concentration profiles for tramadol and M1 according to dosage and CYP2D6 genotypes in the Korean population. Parallel artificial membrane permeation assay was performed to determine tramadol permeability, and the metabolic clearance of M1 was determined using human liver microsomes. Clinical study data were used to develop the model. Other physicochemical and pharmacokinetic parameters were obtained from the literature. Simulations for plasma concentrations of tramadol and M1 (after 100 mg tramadol was administered five times at 12-h intervals) were based on a total of 1000 virtual healthy Koreans using SimCYP® simulator. -
Opioid Receptorsreceptors
OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors. -
Oral Drug Delivery System Comprising High Viscosity
(19) & (11) EP 1 575 569 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/52 (2006.01) 29.09.2010 Bulletin 2010/39 (86) International application number: (21) Application number: 03799943.0 PCT/US2003/040156 (22) Date of filing: 15.12.2003 (87) International publication number: WO 2004/054542 (01.07.2004 Gazette 2004/27) (54) ORAL DRUG DELIVERY SYSTEM COMPRISING HIGH VISCOSITY LIQUID CARRIER MATERIALS ORALE DARREICHUNGSFORM MIT FLÜSSIGEN HOCHVISKOSEN TRÄGERSYSTEMEN FORME D’ADMINISTRATION ORALE DE MEDICAMENTS COMPRENANT UN VEHICULE LIQUIDE DE HAUTE VISCOSITE (84) Designated Contracting States: • GIBSON, John, W. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Sprinville, AL 35146 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR • MIDDLETON, John, C. Birmingham, AL 35244 (US) (30) Priority: 13.12.2002 US 433116 P 04.11.2003 US 517464 P (74) Representative: Woods, Geoffrey Corlett J.A. Kemp & Co. (43) Date of publication of application: 14 South Square 21.09.2005 Bulletin 2005/38 Gray’s Inn London (60) Divisional application: WC1R 5JJ (GB) 10003425.5 / 2 218 448 (56) References cited: (73) Proprietor: Durect Corporation GB-A- 2 238 478 US-A- 5 266 331 Cupertino, CA 95014-4166 (US) US-B1- 6 413 536 (72) Inventors: • SULLIVANS A ET AL: "Sustained release of orally • YUM, Su, Il administered active using SABER(R) delivery Los Altos, CA 94024 (US) system incorporated into soft gelatin capsules" • SCHOENHARD, Grant PROCEEDINGS OF THE CONTROLLED San Carlos, CA 94070 (US) RELEASE SOCIETY 1998 UNITED STATES, no. -
1 Opioid Receptor
Neuron, Vol. 11, 903-913, November, 1993, Copyright 0 1993 by Cell Press Cloning and Pharmacological Characterization of a Rat ~1Op ioid Receptor Robert C. Thompson, Alfred Mansour, Huda Akil, cortex, and have been shown to bind enkephalin-like and Stanley 1. Watson peptides (Mansour et al., 1988; Wood, 1988). 6 recep- Mental Health Research Institute tors are also thought to modulate several hormonal University of Michigan systems and to mediate analgesia. Ann Arbor, Michigan 48109-0720 The p receptors represent the third member of the opioid receptor family.These receptors bind morphine- like drugs and several endogenous opioid peptides, Summary including P-endorphin (derived from proopiomelano- cortin) and several members of both the enkephalin We have isolated a rat cDNA clone that displays 75% and the dynorphin opioid peptide families. These re- amino acid homology with the mouse 6 and rat K opioid ceptors have been localized in many regions of the receptors. The cDNA (designated pRMuR-12) encodes CNS, including the striatum (striatal patches), thalamus, a protein of 398 amino acids comprising, in part, seven nucleus tractus solitarius, and spinal cord (Mansour hydrophobic domains similar to those described for other et al., 1987; McLean et al., 1986; Temple and Zukin, 1987; C protein-linked receptors. Data from binding assays Wood, 1988; Mansour and Watson, 1993). p receptors conducted with COS-1 cells transiently transfected with appear to mediate the opiate phenomena classically a CMV mammalian expression vector containing the full associated with morphine and heroin administration, coding region of pRMuR-12 demonstrated p receptor including analgesia, opiate dependence, cardiovascu- selectivity. -
Salvinorin a and Related Compounds As Therapeutic Drugs for Psychostimulant-Related Disorders
See discussions, stats, and author profiles for this publication at: http://www.researchgate.net/publication/270217015 Salvinorin A and related compounds as therapeutic drugs for psychostimulant-related disorders ARTICLE in CURRENT DRUG ABUSE REVIEWS · OCTOBER 2014 DOWNLOADS VIEWS 53 322 4 AUTHORS, INCLUDING: Rafael Guimarães dos Santos João Paulo Machado-de-Sousa Ribeirão Preto Medical School, University of … University of São Paulo 35 PUBLICATIONS 114 CITATIONS 41 PUBLICATIONS 394 CITATIONS SEE PROFILE SEE PROFILE Available from: Rafael Guimarães dos Santos Retrieved on: 16 August 2015 Send Orders for Reprints to [email protected] 128 Current Drug Abuse Reviews, 2014, 7, 128-132 Salvinorin A and Related Compounds as Therapeutic Drugs for Psychostimulant-Related Disorders R.G. dos Santos*,1, J.A.S. Crippa1,2, J.P. Machado-de-Sousa1,2 and J.E.C. Hallak1,2 1Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, SP, Brazil 2National Institute for Translational Medicine (INCT-TM), CNPq, Brazil Abstract: Pharmacological treatments are available for alcohol, nicotine, and opioid dependence, and several drugs for cannabis-related disorders are currently under investigation. On the other hand, psychostimulant abuse and dependence lacks pharmacological treatment. Mesolimbic dopaminergic neurons mediate the motivation to use drugs and drug-induced euphoria, and psychostimulants (cocaine, amphetamine, and methamphetamine) produce their effects in these neurons, which may be modulated by the opioid system. Salvinorin A is a κ-opioid receptor agonist extracted from Salvia divinorum, a hallucinogenic plant used in magico-ritual contexts by Mazateca Indians in México. Salvinorin A and its analogues have demonstrated anti-addiction effects in animal models using psychostimulants by attenuating dopamine release, sensitization, and other neurochemical and behavioral alterations associated with acute and prolonged administration of these drugs. -
Molecular Changes in Opioid Addiction: the Role of Adenylyl Cyclase and Camp/PKA System 205
CHAPTER SEVEN Molecular Changes in Opioid Addiction: The Role of Adenylyl Cyclase and cAMP/PKA System ,1 † Patrick Chan* , Kabirullah Lutfy * Department of Pharmacy and Pharmacy Administration, Western University of Health Sciences, College of Pharmacy, Pomona, California, USA † Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA 1 Corresponding author: e-mail address: [email protected]. Contents 1. Introduction 204 2. The Adenylyl Cyclase Pathway 205 2.1 Adenylyl Cyclase 205 2.2 Protein Kinase A 207 3. Opioid Effect on cAMP-Responsive Element-Binding Protein 209 4. Molecular Changes in Brain Regions That May Underlie Opiate Dependence 211 4.1 Molecular Changes in the Locus Coeruleus 211 4.2 Molecular Changes in the Amygdala 214 4.3 Molecular Changes in the Periaqueductal Gray 216 5. Molecular Changes in the Ventral Tegmental Area 217 6. Molecular Changes in Other CNS Regions 218 7. Conclusions 219 References 219 Abstract For centuries, opiate analgesics have had a considerable presence in the treatment of moderate to severe pain. While effective in providing analgesia, opiates are notorious in exerting many undesirable adverse reactions. The receptor targets and the intra- cellular effectors of opioids have largely been identified. Furthermore, much of the mechanisms underlying the development of tolerance, dependence, and withdrawal have been delineated. Thus, there is a focus on developing novel compounds or strategies in mitigating or avoiding the development of tolerance, dependence, and withdrawal. This review focuses on the adenylyl cyclase and cyclic adenosine 3,5-monophosphate (cAMP)/protein kinase A (AC/cAMP/PKA) system as the central player in mediating the acute and chronic effects of opioids. -
CNS Drug Reviews Vol
CNS Drug Reviews Vol. 11, No. 2, pp. 195–212 © 2005 Neva Press, Branford, Connecticut Bremazocine: A ê-Opioid Agonist with Potent Analgesic and Other Pharmacologic Properties Juanita Dortch-Carnes1 and David E. Potter2 1Department of Pharmacology/Toxicology, Morehouse School of Medicine, Atlanta, GA, USA; 2Department of Ophthalmology, Storm Eye Institute, Medical University of South Carolina, Charleston, SC, USA Keywords: Analgesia — Bremazocine — Diuresis — Dysphoria — ê-Opioid agonists — Ocu- lar hypotension — Respiration. ABSTRACT Bremazocine is a ê-opioid receptor agonist with potent analgesic and diuretic activities. As an analgesic it is three- to four-times more potent than morphine, as determined in both hot plate and tail flick tests. Bremazocine and other benzomorphan analogs were synthe- sized in an effort to produce opiates with greater ê-opioid receptor selectivity and with minimal morphine-like side effects. Unlike morphine bremazocine is devoid of physical and psychological dependence liability in animal models and produces little or no respi- ratory depression. While bremazocine does not produce the characteristic euphoria asso- ciated with morphine and its abuse, it has been shown to induce dysphoria, a property that limits its clinical usefulness. Similarly to morphine, repeated administration of bremazo- cine leads to tolerance to its analgesic effect. It has been demonstrated that the marked di- uretic effect of bremazocine is mediated primarily by the central nervous system. Because of its psychotomimetic side effects (disturbance in the perception of space and time, abnormal visual experience, disturbance in body image perception, de-personaliza- tion, de-realization and loss of self control) bremazocine has limited potential as a clinical analgesic. -
Review Article Tramadol Extended-Release for the Management of Pain Due to Osteoarthritis
Hindawi Publishing Corporation ISRN Pain Volume 2013, Article ID 245346, 16 pages http://dx.doi.org/10.1155/2013/245346 Review Article Tramadol Extended-Release for the Management of Pain due to Osteoarthritis Chiara Angeletti, Cristiana Guetti, Antonella Paladini, and Giustino Varrassi Anesthesiology and Pain Medicine, University of L’Aquila, Viale San Salvatore, Edificio 6, Coppito, 67100 L’Aquila, Italy Correspondence should be addressed to Chiara Angeletti; [email protected] Received 11 February 2013; Accepted 29 April 2013 Academic Editors: M. I. D´ıaz-Reval, G. Krammer, and A. Ulugol Copyright © 2013 Chiara Angeletti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Current knowledge on pathogenesis of osteoarticular pain, as well as the consequent several, especially on the gastrointestinal, renal, and cardiovascular systems, side effects of NSAIDs, makes it difficult to perform an optimal management of thismixed typology of pain. This is especially observable in elderly patients, the most frequently affected by osteoarthritis (OA). Tramadol is an analgesic drug, the action of which has a twofold action. It has a weak affinity to mu opioid receptors and, at the same time, can result in inhibition of the reuptake of noradrenaline and serotonin in nociceptorial descending inhibitory control system. These two mechanisms, “opioidergic” and “nonopioidergic,” are the grounds for contrasting certain types of pain that are generally less responsive to opioids, such as neuropathic pain or mixed OA pain. The extended-release formulation of tramadol has good efficacy and tolerability and acts through a dosing schedule that allows a high level of patients compliance to therapies with a good recovery outcome for the patients’ functional status. -
The Role of the Endocannabinoid System
International Journal of Molecular Sciences Review The Impact of Early Life Exposure to Cannabis: The Role of the Endocannabinoid System Annia A. Martínez-Peña 1,2,†, Genevieve A. Perono 1,2,† , Sarah Alexis Gritis 2, Reeti Sharma 3, Shamini Selvakumar 3, O’Llenecia S. Walker 2,3, Harmeet Gurm 2,3, Alison C. Holloway 1,2 and Sandeep Raha 2,3,* 1 Graduate Program in Medical Sciences, McMaster University, Hamilton, ON L8S 4K1, Canada; [email protected] (A.A.M.-P.); [email protected] (G.A.P.); [email protected] (A.C.H.) 2 Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON L8S 4K1, Canada; [email protected] (S.A.G.); [email protected] (O.S.W.); [email protected] (H.G.) 3 Department of Pediatrics, McMaster University, Hamilton, ON L8S 4K1, Canada; [email protected] (R.S.); [email protected] (S.S.) * Correspondence: [email protected]; Tel.: +1-905-521-2100 (ext. 76213) † These authors contributed equally to the preparation of this manuscript. Abstract: Cannabis use during pregnancy has continued to rise, particularly in developed countries, as a result of the trend towards legalization and lack of consistent, evidence-based knowledge on the matter. While there is conflicting data regarding whether cannabis use during pregnancy leads to adverse outcomes such as stillbirth, preterm birth, low birthweight, or increased admission to neonatal intensive care units, investigations into long-term effects on the offspring’s health are limited. Historically, studies have focused on the neurobehavioral effects of prenatal cannabis exposure on Citation: Martínez-Peña, A.A.; the offspring. -
NIDA Drug Supply Program Catalog, 25Th Edition
RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25 -
Involvement of Serotonergic and Opioidergic Systems in the Antinociceptive Effect of Ketamine-Magnesium Sulphate Combination In
Pharmacological Reports 71 (2019) 1014–1019 Contents lists available at ScienceDirect Pharmacological Reports journal homepage: www.elsevier.com/locate/pharep Original article Involvement of serotonergic and opioidergic systems in the antinociceptive effect of ketamine-magnesium sulphate combination in formalin test in rats a, a b a Katarina Savic Vujovic *, Sonja Vuckovi9 c , Dolika Vasovic , Branislava Medic , a a a a Radan Stojanovic , Nevena Divac , Dragana Srebro , Milica Prostran a Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia b Faculty of Medicine, University of Belgrade, Belgrade, Serbia A R T I C L E I N F O A B S T R A C T Article history: Introduction: Ketamine and magnesium sulphate showed synergic interaction in the tail-immersion test Received 14 December 2018 and additive interaction in the rat formalin test. Aim of study was to evaluate the influence of Received in revised form 5 April 2019 serotonergic and opioidergic system of this combination in the formalin test in rats. Accepted 24 May 2019 Methods: Antinociceptive activity was assessed by the formalin test in male Wistar rats (200–250 g). Available online 25 May 2019 Antagonists (naloxone and methysergide) were administrated 5 min before and magnesium sulphate 5 min after ketamine injection. Formalin (2.5%, 100 mL) was injected into the right hind paw surface Keywords: (intraplantar) of rats 5 min after ketamine/magnesium combination. Data were recorded as the total time Ketamine spent in pain related behavior after the injection of formalin or vehicle (0.9% NaCl). Magnesium Inflammation Results: In the intermediate phase of the formalin test, methysergide at a dose of 0.2 mg/kg did not have Serotonergic any effect, but at doses of 0.5 and 1 mg/kg it had a pronociceptive effect.